Casma Therapeutics, a Cambridge biotech trying to develop new medicines based on discoveries about how cells detoxify and repair themselves, has raised $50 million in fresh venture capital and wants to use the money to create drugs for treating muscular dystrophy.

It’s the second fund-raising round for Casma, which was launched by Boston-based Third Rock Ventures in 2018 with $58 million in venture capital. The latest fund-raising effort was led by The Column Group, of Pacifica, Calif., and added several new investors, including Eventide Asset Management of Boston and Swiss-based Schroder Adveq.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy